Abstract: Poster Presentations |


Lawrence Lottenberg, MD, FACS*; Gretchen M. Brophy, PharmD; Marc J. Shapiro, MD; Debra Scarlata, MS; Paul Audhya, MD
Author and Funding Information

University of Florida, Gainesville, FL

Chest. 2006;130(4_MeetingAbstracts):217S-d-218S. doi:10.1378/chest.130.4_MeetingAbstracts.217S-d
Text Size: A A A
Published online


PURPOSE: This analysis of ASSESS, a multicenter, retrospective hospital chart review, evaluated patient characteristics, dosing patterns and hemoglobin (Hb) outcomes associated with erythropoiesis-stimulating protein (ESP) use in anemic, hospitalized surgical patients.

METHODS: Data were abstracted from charts of adult hospitalized surgical patients not requiring hemodialysis. Nine hospitals used darbepoetin alfa (DA); 10 used Epoetin alfa (EA). Attempts were made to balance hospital type, number of beds, and trauma center designation. Eligible patients were hospitalized ≥24 hrs; had received ≥1 dose of either ESP (but not both) in the hospital; had ≥2 Hb measurements (1 before and 1 after the first dose).

RESULTS: Mean (SD) baseline Hb closest to but before the first ESP dose was 9.2 (1.9) and 9.5 (1.5) g/dL in patients receiving DA (n=209) or EA (n=307), respectively. The most common surgeries for DA and EA patients were pulmonary- (29% and 25%, respectively) and gastrointestinal/abdominal-related (28% and 21%, respectively). Patients received a median (25%, 75%) dose of 53 (33, 82) mcg of DA or 18667 (10000, 30000) IU of EA per week of hospital stay. Of patients receiving DA, 85% were prescribed once-weekly dosing; of EA patients, 36% were prescribed thrice-weekly and 30% once-weekly dosing. The mean (SD) change in Hb from baseline to discharge was 0.7 (1.6) and 0.5 (1.7) g/dL for patients receiving DA or EA, respectively; the median (25%, 75%) length of hospital stay was 22 (13, 40) and 15 (9, 27) days, respectively. Transfusion independence after ESP initiation was achieved by 50% of DA and 53% of EA patients.

CONCLUSION: Based on descriptive statistics, and despite a longer length of stay for DA-receiving patients suggesting a more complicated patient population, Hb outcomes and transfusion independence associated with the reported ESP doses were similar from a clinical perspective for hospitalized surgical patients receiving DA or EA.

CLINICAL IMPLICATIONS: Provides a better understanding of dosing patterns and clinical outcomes associated with ESP use, which is not well characterized in the treatment of anemia in hospitalized surgical patients.

DISCLOSURE: Lawrence Lottenberg, Grant monies (from industry related sources) L. Lottenberg, Amgen Inc. GM Brophy, Amgen Inc. MJ Shapiro, Amgen Inc.; Shareholder D. Scarlata, Amgen Inc. P. Audhya, Amgen Inc. Wife of L. Lottenberg, Amgen Inc.; Employee D. Scarlata, Amgen Inc. P. Audhya, Amgen Inc. Wife of L. Lottenberg, Amgen Inc.; Consultant fee, speaker bureau, advisory committee, etc. G.M. Brophy, Amgen Inc. and Ortho Biotech; Product/procedure/technique that is considered research and is NOT yet approved for any purpose, Inpatient use of darbepoetin alfa and Epoetin alfa for the treatment of anemia after surgery.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543